ZEUS does not end inflammation drug discovery – it raises the bar

Novo’s ziltivekimab failure challenges the “lower hsCRP, improve outcomes” thesis – DLT data point to NLRP3 and senescent-cell biology next. Novo Nordisk’s phase 3 ZEUS failure has shaken the cardiovascular inflammation field. Ziltivekimab was designed to block interleukin-6, a cytokine associated with residual inflammatory risk in patients with cardiovascular disease. In ZEUS, the drug produced […] The post ZEUS does not end inflammation drug discovery – it raises the bar appeared first on Longevity.Technology .

This story was reported by Longevity.Technology. EUROPES curates Europe's most relevant coverage — read the full report at the original source.